Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concernNicotiana benthamiana에서 생산된 SARS-CoV-2 변이체의 수용체 결합 도메인 단백질은 우려되는 변이체에 대한 중화 항체를 유도합니다Article Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] (alpha Alpha Beta binding domain booster vaccination Booster vaccine cloned COVID-19 cross-reactive Day Delta Delta variants dose Effective vaccines elicit Epsilon evaluated expression vector Fc fragment fragment of Gamma gene encoding health problem human IgG1 immune response immunized immunogenicity induce intramuscularly mutant Mutation Neutralizing antibodies neutralizing antibody Neutralizing antibody response neutralizing antibody responses Nicotiana benthamiana plant-produced recombinant protein produced Protein public health RBD RBD-Fc RBD-Fc fusion protein Receptor-binding domain Recombinant protein required respiratory SARS-CoV-2 SARS-CoV-2 strains SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome significantly Spread subunit Subunit vaccine tested the receptor-binding domain the vaccine the vaccines transient expression Vaccine variant variant vaccine. variants variants of concern VOCs Wuhan [DOI] 10.1002/jmv.27881 PMC 바로가기 [Article Type] Article
Acceptance of Different Self-sampling Methods for Semiweekly SARS-CoV-2 Testing in Asymptomatic Children and Childcare Workers at German Day Care Centers: A Nonrandomized Controlled TrialArticle Published on 2022-09-012022-11-15 Journal: JAMA Network Open [Category] SARS, 치료기술, [키워드] 95% CI acceptance Antigen Asymptomatic Care children clinical closure conducted Controlled Course COVID-19 pandemic Day DCC Effect eligible Germany Health highest incidence incidence rates initial median nasal nonrandomized outcome participated Participation PCR performed pilot study polymerase chain Probability ranged registry Saliva SARS-CoV-2 SARS-CoV-2 PCR test SARS-CoV-2 surveillance SARS-CoV-2 testing subsequent Testing threshold Weekly women worker [DOI] 10.1001/jamanetworkopen.2022.31798 PMC 바로가기
Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USAArticle Published on 2022-09-012022-11-16 Journal: Emerging Infectious Diseases [Category] SARS, 변종, [키워드] acute respiratory syndrome coronavirus coronavirus disease COVID-19 COVID-19 vaccination Day first positive omicron Pennsylvania respiratory infections SARS-CoV-2 SARS-CoV-2 test severe acute respiratory syndrome coronavirus 2 suggested symptomatic infection symptomatic SARS-CoV-2 infection United States USA vaccine-preventable diseases variant viruses whole-genome sequencing zoonoses zoonoses. [DOI] 10.3201/eid2809.220539 PMC 바로가기
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article
Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: A prospective longitudinal study초등학교에서 SARS-CoV-2 발병(알파 변종)에 대한 역학, 바이러스 및 혈청학적 조사: 전향적 종단 연구Article Published on 2022-08-172022-09-11 Journal: PLoS ONE [Category] SARS, 변종, 진단, 치료기술, [키워드] Alpha Alpha variant analysed attack rate attack rates capillary blood Child children circulation Community Contact tracing Day epidemiological Households identity infected children involved limit measure outbreak participant positive primary school pupil Pupils rapid antigen test Rapid antigen tests reduce repeated reported RT-PCR SARS-CoV-2 SARS-CoV-2 transmission School Schools secondary secondary attack rate sequence Sequencing Seroconversion serological serological test Serological tests serology Surveillance tested Transmission Virological virological tests were infected whole genome Whole genome sequencing [DOI] 10.1371/journal.pone.0272663 PMC 바로가기 [Article Type] Article
Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment리툭시맙 치료 환자에서 SARS-CoV-2 감염 후 90일 동안 지속되는 발열 및 PCR 양성: 후기 항바이러스 치료 1례Case Reports Published on 2022-08-112022-09-11 Journal: Viruses [Category] SARS, 진단, 치료제, [키워드] Antiviral treatment antivirals B cell B cell immune responses benefit Day defined diagnostic dominant Dyspnea early treatment feasible Fever full recovery high fever Hospitalized human long-term infection hyperinflammation Hypoxemia immune immune responses Immunocompromised Immunocompromised patients immunosuppressive immunosuppressive therapy infusion interval low-grade viral replication lower airway lower airways lung infiltrate lung infiltrates Mild mild to moderate moderate monoclonal monoclonal antibodies monoclonal antibody multiple sclerosis Patient patients PCR persistent persistent fever positive PCR test post infection Prophylactic receiving reduced reported Respiratory failure rituximab rituximab. SARS-CoV-2 SARS-COV-2 infection sensitivity serum severe respiratory failure Symptom therapy Treatment treatment approach treatment approaches Viral viral replication [DOI] 10.3390/v14081757 PMC 바로가기 [Article Type] Case Reports
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trialRandomized Controlled Trial Published on 2022-08-092022-10-04 Journal: Respiratory Research [Category] SARS, 임상, [키워드] 95% CI 95% confidence interval age Antibiotic prophylaxis assigned baseline Clinical outcome complement Complement 5 complement system Concentration control group COVID-19 COVID-19 patient Day Efficacy and safety Hypoxemia Inflammation inhibitor long-term follow up mean difference men Mortality MOST multicenter Odds ratio Open-label Oxygenation PaO Patient patients hospitalized primary analysis Primary outcome Randomized Randomized controlled trial randomized studies randomized trial Randomly receive Research Respiratory function serum Standard of care statistical significance systemic systemic inflammation systemic inflammation. the median Trial while zilucoplan [DOI] 10.1186/s12931-022-02126-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
Decline of onset-to-diagnosis interval and its impacts on clinical outcome of COVID-19 in China: a nation-wide observational studyObservational Study Published on 2022-08-052022-10-04 Journal: BMC Infectious Diseases [Category] SARS, 임상, [키워드] 95% CI age benefit Case fatality rate CFR China Clinical outcome conducted coronavirus disease COVID-19 COVID-19 case Day death Decline Diagnosis discrepancy dropped early diagnosis evaluated fatality Fatality rate fraction greater highest highlighting Impact magnitude Male sex Onset-to-diagnosis interval Patient patients reported Retrospective study Severe rate. severity severity of COVID-19 Sex significantly System Wuhan [DOI] 10.1186/s12879-022-07660-4 PMC 바로가기 [Article Type] Observational Study
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial건강한 성인을 대상으로 한 단일 용량 V590(rVSV-SARS-CoV-2 Vaccine)의 근육 내 안전성 및 면역원성: 1상 무작위 배정, 이중 맹검, 위약 대조, 용량 범위 시험 결과Clinical Trial Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] Administered administration Adults adverse event adverse events AEs anti-SARS-CoV-2 Antibody responses comparable COVID-19 COVID-19 vaccine Day dose double-blind Endpoint fatigue global pandemic headache healthy highest dose immunogenicity Inc. Injection-site pain intramuscular lower dose neutralisation neutralising antibody response Older overcome Part participant pfu Phase 1 phase 1 study Placebo placebo-controlled plaque plaque-forming unit plaque-forming units primary endpoints PRNT50 randomised receive reduction Registration reported Result Safety SARS-CoV-2 SARS-CoV-2 nucleocapsid seronegative seronegative participant seronegative participants seropositive serum Sharp spike-specific antibody response stomatitis subsidiary Trial USA V590 Vaccine vesicular stomatitis vesicular stomatitis virus Vesicular stomatitis virus (VSV). virus VSV [DOI] 10.1016/j.ebiom.2022.104138 PMC 바로가기 [Article Type] Clinical Trial